259 related articles for article (PubMed ID: 33407602)
1. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.
Xu Y; Ma X; Zhou Z; Li J; Hou J; Zhu J; Kang M; Lai J; Li X
Pediatr Rheumatol Online J; 2021 Jan; 19(1):2. PubMed ID: 33407602
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
Wang X; Ding Y; Zhou Z; Hou J; Xu Y; Li J
Pediatr Rheumatol Online J; 2021 Jan; 19(1):6. PubMed ID: 33407621
[TBL] [Abstract][Full Text] [Related]
3. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
4. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
Aouizerate J; De Antonio M; Bader-Meunier B; Barnerias C; Bodemer C; Isapof A; Quartier P; Melki I; Charuel JL; Bassez G; Desguerre I; Gherardi RK; Authier FJ; Gitiaux C
Rheumatology (Oxford); 2018 May; 57(5):873-879. PubMed ID: 29474663
[TBL] [Abstract][Full Text] [Related]
5. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
6. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
7. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
8. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
[TBL] [Abstract][Full Text] [Related]
9. Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.
Fu Y; Gu L; Chen J; Dai Y; Feng Q; Chen Z; Fan J; Gao M; Wang X; Fu Q; Ye S
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199847
[TBL] [Abstract][Full Text] [Related]
10. [The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis].
Li DM; Wang L; Liu MY; Xu L; Tang XM
Zhonghua Er Ke Za Zhi; 2020 Dec; 58(12):966-972. PubMed ID: 33256317
[No Abstract] [Full Text] [Related]
11. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
[TBL] [Abstract][Full Text] [Related]
12. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
Yamasaki Y; Kobayashi N; Akioka S; Yamazaki K; Takezaki S; Nakaseko H; Ohara A; Nishimura K; Nishida Y; Sato S; Kishi T; Hashimoto M; Mori M; Okazaki Y; Kuwana M; Ohta A
Rheumatology (Oxford); 2021 Oct; 60(10):4821-4831. PubMed ID: 33576399
[TBL] [Abstract][Full Text] [Related]
14. Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature.
Chang Y; Shan X; Ge Y
Pediatr Rheumatol Online J; 2023 Sep; 21(1):106. PubMed ID: 37735702
[TBL] [Abstract][Full Text] [Related]
15. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
16. Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.
Toplak N; Pimpale Chavan P; Rosina S; Dallos T; Rotem Semo O; Aguiar CL; Khubchandani R; Ravelli A; Patwardhan A
Front Pediatr; 2021; 9():810785. PubMed ID: 35280444
[TBL] [Abstract][Full Text] [Related]
17. [Juvenile dermatomyositis and new autoantibodies: Cases and review].
Guarella M; Jurquet AL; Retornaz K; Bardin N; Chastang MC; Desjonquere M; Fabien N; Belot A
Arch Pediatr; 2015 Dec; 22(12):1263-7. PubMed ID: 26598044
[TBL] [Abstract][Full Text] [Related]
18. Anti-NXP2 antibody-associated extensive subcutaneous calcinosis in adult-onset myositis.
Goulabchand R; Guilpain P; Cyteval C; Le Quellec A
Rheumatology (Oxford); 2017 Oct; 56(10):1661. PubMed ID: 28605526
[No Abstract] [Full Text] [Related]
19. Medications received by patients with juvenile dermatomyositis.
Kishi T; Bayat N; Ward MM; Huber AM; Wu L; Mamyrova G; Targoff IN; Warren-Hicks WJ; Miller FW; Rider LG;
Semin Arthritis Rheum; 2018 Dec; 48(3):513-522. PubMed ID: 29773230
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.
Mathiesen PR; Buchvald F; Nielsen KG; Herlin T; Friis T; Nielsen S
Rheumatology (Oxford); 2014 Apr; 53(4):644-9. PubMed ID: 24310298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
